These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 21810054)

  • 41. Dormancy models for Mycobacterium tuberculosis: A minireview.
    Alnimr AM
    Braz J Microbiol; 2015; 46(3):641-7. PubMed ID: 26413043
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonclinical models for antituberculosis drug development: a landscape analysis.
    Gumbo T; Lenaerts AJ; Hanna D; Romero K; Nuermberger E
    J Infect Dis; 2015 Jun; 211 Suppl 3():S83-95. PubMed ID: 26009617
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging drugs and alternative possibilities in the treatment of tuberculosis.
    Hofman S; Segers MM; Ghimire S; Bolhuis MS; Sturkenboom MG; Van Soolingen D; Alffenaar JW
    Expert Opin Emerg Drugs; 2016; 21(1):103-16. PubMed ID: 26848966
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development.
    Nuermberger E; Sizemore C; Romero K; Hanna D
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1177-82. PubMed ID: 26824941
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Progress in TB drug development and what is still needed.
    Duncan K
    Tuberculosis (Edinb); 2003; 83(1-3):201-7. PubMed ID: 12758212
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biomarkers of treatment response in clinical trials of novel antituberculosis agents.
    Perrin FM; Lipman MC; McHugh TD; Gillespie SH
    Lancet Infect Dis; 2007 Jul; 7(7):481-90. PubMed ID: 17524807
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.
    Gumbo T; Pasipanodya JG; Romero K; Hanna D; Nuermberger E
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S25-31. PubMed ID: 26224769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advancing tuberculosis drug regimen development through innovative quantitative translational pharmacology methods and approaches.
    Hanna D; Romero K; Schito M
    Int J Infect Dis; 2017 Mar; 56():208-211. PubMed ID: 27789338
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations.
    Clewe O; Wicha SG; de Vogel CP; de Steenwinkel JEM; Simonsson USH
    J Antimicrob Chemother; 2018 Feb; 73(2):437-447. PubMed ID: 29136155
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Models for disease progression: new approaches and uses.
    Mould DR
    Clin Pharmacol Ther; 2012 Jul; 92(1):125-31. PubMed ID: 22617225
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases.
    He S; Gui J; Xiong K; Chen M; Gao H; Fu Y
    J Nanobiotechnology; 2022 Mar; 20(1):101. PubMed ID: 35241085
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis.
    Ernest JP; Strydom N; Wang Q; Zhang N; Nuermberger E; Dartois V; Savic RM
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():495-516. PubMed ID: 32806997
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of the host environment on the antitubercular action of pyrazinamide.
    Lamont EA; Baughn AD
    EBioMedicine; 2019 Nov; 49():374-380. PubMed ID: 31669220
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of biomedical research in global tuberculosis control: gaps and challenges: A perspective from the US National Institute of Allergy and Infectious Diseases, National Institutes of Health.
    Sizemore CF; Schleif AC; Bernstein JB; Heilman CA
    Emerg Microbes Infect; 2012 Jul; 1(7):e9. PubMed ID: 26038420
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Challenges and opportunities in developing novel drugs for TB.
    Kaneko T; Cooper C; Mdluli K
    Future Med Chem; 2011 Sep; 3(11):1373-400. PubMed ID: 21879843
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Course of murine tuberculosis and response to first-line therapy depends on route of infection and inoculum size.
    de Steenwinkel JE; ten Kate MT; de Knegt GJ; Verbrugh HA; van Belkum A; Hernandez-Pando R; Bakker-Woudenberg IA
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1478-84, i. PubMed ID: 22008760
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Models and approaches for anti-TB drug testing.
    Yasinskaya Y; Sacks L
    Expert Rev Anti Infect Ther; 2011 Jul; 9(7):823-31. PubMed ID: 21810054
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.